Literature DB >> 24026888

[Proven and new methods in the treatment of genital warts].

P Schneede1, R Waidelich.   

Abstract

Anogenital warts are the most common clinical manifestation of human papillomavirus (HPV) infections. Although easy to recognize, asymptomatic anogenital warts (condylomata acuminata) may be overlooked, leading to unaware transmission to the sexual partner. On the other hand awareness of this sexually transmitted disease (STD) is largely associated with a great psychological and social burden, in men as well as women. Spontaneous regression of genital warts has been observed mostly within 2-5 years; however, persisting condylomata may prove refractory to all current treatment options. Because removal of the warts does not totally eliminate the underlying viral infection, treatment of genital warts can often be of long duration, of varying effectiveness and with high recurrence rates. Without a doubt only the patient's own immune system is capable of clearing HPV infections. Therefore, the solution to one of mankind's oldest health problems will depend on the future acceptability of HPV vaccines.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24026888     DOI: 10.1007/s00120-013-3174-9

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  28 in total

1.  Incidence of concurrent sexually transmitted infections in patients with genital warts.

Authors:  V Griffiths; W-H Cheung; E M Carlin; I Ahmed-Jushuf
Journal:  Int J STD AIDS       Date:  2006-06       Impact factor: 1.359

2.  [Urethral condyloma in a patient with neurogenic bladder dysfunction: a therapeutic challenge].

Authors:  P Bartel; K Göcking; J Pannek
Journal:  Urologe A       Date:  2013-01       Impact factor: 0.639

3.  Risk factors for the acquisition of genital warts: are condoms protective?

Authors:  L M Wen; C S Estcourt; J M Simpson; A Mindel
Journal:  Sex Transm Infect       Date:  1999-10       Impact factor: 3.519

Review 4.  Prevalence of HPV infection among men: A systematic review of the literature.

Authors:  Eileen F Dunne; Carrie M Nielson; Katherine M Stone; Lauri E Markowitz; Anna R Giuliano
Journal:  J Infect Dis       Date:  2006-09-12       Impact factor: 5.226

5.  A randomized trial of immunotherapy for persistent genital warts.

Authors:  David Jardine; Jieqiang Lu; James Pang; Cheryn Palmer; Quanmei Tu; John Chuah; Ian H Frazer
Journal:  Hum Vaccin Immunother       Date:  2012-05-01       Impact factor: 3.452

6.  [Human papillomaviruses (HPV) in urology. II: 10 years evaluation of differential HPV therapy].

Authors:  P Schneede; A Hofstetter
Journal:  Urologe A       Date:  2002-01       Impact factor: 0.639

Review 7.  Human papillomavirus-related disease in people with HIV.

Authors:  Joel Palefsky
Journal:  Curr Opin HIV AIDS       Date:  2009-01       Impact factor: 4.283

Review 8.  Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe: a review.

Authors:  Susanne Hartwig; Stina Syrjänen; Géraldine Dominiak-Felden; Maria Brotons; Xavier Castellsagué
Journal:  BMC Cancer       Date:  2012-01-20       Impact factor: 4.430

Review 9.  Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model.

Authors:  Ralph P Insinga; Erik J Dasbach; Elamin H Elbasha
Journal:  BMC Infect Dis       Date:  2009-07-29       Impact factor: 3.090

Review 10.  HPV infection, anal intra-epithelial neoplasia (AIN) and anal cancer: current issues.

Authors:  Margaret A Stanley; David M Winder; Jane C Sterling; Peter K C Goon
Journal:  BMC Cancer       Date:  2012-09-08       Impact factor: 4.430

View more
  3 in total

Review 1.  [Human papillomavirus disease burden in men : HPV prevention is a man's business].

Authors:  P Schneede
Journal:  Urologe A       Date:  2018-12       Impact factor: 0.639

Review 2.  [Anogenital warts and HPV-associated precancers : Looking into the recently passed German S2k guideline].

Authors:  P Schneede; B Schlenker
Journal:  Urologe A       Date:  2018-04       Impact factor: 0.639

Review 3.  [One decade of HPV vaccination in Germany].

Authors:  P Schneede
Journal:  Urologe A       Date:  2017-06       Impact factor: 0.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.